Martin SA, Chen K, Harris NI, Vera-Llonch M. Development of a patient-reported outcome measure for chronic hypoparathyroidism. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A679.
White M, Hogue S, Odom D, Cooney D, Bartsch J, Hollis K, Herrem C, Silvia S. EPIPEN4SCHOOLS® survey combined analysis: a comprehensive assessment of anaphylaxis in US schools. Presented at the 2016 AAP National Conference & Exhibition; October 22, 2016. Sacramento, CA.
Mease P, Coates LC, Kirkham B, McLeod LD, Mpofu S, Karyekar C, Gandhi K. Secukinumab improves minimal disease activity response rates in patients with active psoriatic arthritis: data from phase 3 FUTURE-2 study. Poster presented at the 10th International Congress on Spondyloarthritides; September 2016. Gent, Belgium. Previously presented at the 2016 Annual European Congress of Rheumatology (EULAR).
White MV, Hogue SL, Odom D, Cooney D, Bartsch J, Goss D, Hollis K, Herrem C, Silvia S. Anaphylaxis in schools: results of the EPIPEN4SCHOOLS survey combined analysis. Pediatr Allergy Immunol Pulmonol. 2016 Sep;29(3):149-54. doi: 10.1089/ped.2016.0675
White MV, Silvia S, Hollis K, Goss D, Odom D, Bartsch J, Hogue SL. EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events. Poster presented at the NASN 2016 48th Annual Conference; June 30, 2016. Indianapolis, IN. Previously presented at the 2016 AAAAI Annual Meeting.
Gossec L, Kvien TK, Conaghan PG, Ostergaard M, Canete J, Gaillez C, Mpofu S, Davenport E, Jugl S. Reduction in fatigue in patients with active psoriatic arthritis are sustained over 2 years: long-term results of two phase 3 studies with secukinumab. Poster presented at the 2016 European League Against Rheumatism Annual European Congress of Rheumatology (EULAR); June 2016. London, United Kingdom. [abstract] Ann Rheum Dis. 2016 Jun; 75(Suppl 2):351. doi: 10.1136/annrheumdis-2016-eular.2052
Hogue SL, Silvia S, Hollis K. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the NASN 2016 48th Annual Conference; June 2016. Indianapolis, IN. Previously presented at the 2016 ACAAI Conference.
Graham CN, Gunda P, Miles L, Jugl S, Palaka E, McBride D. A new cost-effectiveness framework for modeling ankylosing spondylitis treatments. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A234.
Hogue SL, Silvia S, Hollis K, Goss D, Odom D, Cooney D, White MV. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 19, 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S116. Previously presented at the 2016 ACAAI Conference.
Hogue SL, Silvia S, Hollis K, Wooddell MJ, Goss D, Odom D, Cooney D, White MV. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the 2016 ACAAI Conference; March 4, 2016. Los Angeles, CA.
Kan H, Nagar S, Patel J, Wallace DJ, Molta C, Chang DJ. Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus. Clin Ther. 2016 Mar;38(3):610-24. doi: 10.1016/j.clinthera.2016.01.016
McKenna SP, Wilburn J, Crawford SR, Aryamanesh M, Twiss J. New developments in the Ankylosing Spondylitis Quality of Life (ASQOL) scale. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A314.